ALRN News and Press, Aileron Therapeutics Inc. From 08/25/21

Locust Walk Acquisition LWACU +235% and eFFECTOR Therapeutics announce business combination Pop Culture (NASDAQ:CPOP) +26% develop street dance chain SaaS system to accelerate digital transformation Jiayin Group (NASDAQ:JFIN) +18% on Q2 earnings. Astrotech (NASDAQ:ASTC) +1...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end of 2021 and topline results mid-2022 -- Announces upcoming presentatio...

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, ...

Aileron Therapeutics (ALRN) perks up 5% after initiating a randomized, placebo-controlled clinical trial in the U.S. and in Europe of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer ((NSCLC)) undergoing chemotherapy.The company plans ...

Phase 1b trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing chemotherapy with first-line carboplatin plus pemetrexed Study will evaluate proportion of treatment cycles free of severe hematological and other toxicities, transfusions and the use of grow...

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it is set to join the Russell Microcap® Index at the conclusio...

-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D. and geriatric oncologist Lodovico Balducci, M.D. -- BOSTON, May 19, 2021 (G...

Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out expected at end of 2021 -- ALRN-6924 is designed to deliver selective chemop...

Chemotherapy is built into the treatment regime of nearly every cancer. However, chemotherapy's well-known toxicity can lead to patient discontinuation and poor quality-of-life. Aileron is developing a treatment to address the toxicity of chemotherapy. For further details se...